1. Home
  2. INSG vs CRDF Comparison

INSG vs CRDF Comparison

Compare INSG & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inseego Corp.

INSG

Inseego Corp.

N/A

Current Price

$4.31

Market Cap

84.9M

ML Signal

N/A

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

N/A

Current Price

$0.89

Market Cap

86.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INSG
CRDF
Founded
1996
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
84.9M
86.8M
IPO Year
2000
2012

Fundamental Metrics

Financial Performance
Metric
INSG
CRDF
Price
$4.31
$0.89
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$15.33
$9.63
AVG Volume (30 Days)
441.7K
799.1K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.37
EPS
0.13
N/A
Revenue
$313,832,000.00
$365,993.00
Revenue This Year
$16.21
N/A
Revenue Next Year
$13.28
N/A
P/E Ratio
$30.92
N/A
Revenue Growth
N/A
49.61
52 Week Low
$3.96
$0.76
52 Week High
$21.90
$3.31

Technical Indicators

Market Signals
Indicator
INSG
CRDF
Relative Strength Index (RSI) 24.49 41.71
Support Level N/A $0.76
Resistance Level $12.95 $1.13
Average True Range (ATR) 0.43 0.07
MACD -0.04 0.01
Stochastic Oscillator 5.87 17.72

Price Performance

Historical Comparison
INSG
CRDF

About INSG Inseego Corp.

Inseego Corp is involved in the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things, and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by application software and cloud services designed to enable customers to analyze data insights and configure and manage their hardware easily. It generates maximum revenue from the United States and Canada. The company also has a presence in Europe (including the United Kingdom).

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: